← Oncology Approval Tracker

FDA DECISION ·

Lynparza + abiraterone

olaparib + abiraterone + prednisone or prednisolone · AstraZeneca

FDA approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with metastatic castration-resistant prostate cancer and a deleterious or suspected deleterious BRCA mutation on an FDA-approved companion diagnostic.

LAMPGEN ANALYSIS

Why it matters

FDA limited this PARP inhibitor combination to the BRCA-defined group.

What research teams should watch

Confirm the companion diagnostic result and coordinate steroid, blood-count and blood-pressure monitoring.

PRIMARY RECORDS

Sources